ストックスクリーナーアプリを入手
6.82
3.18%
0.21
アフターアワーズ：
6.76
-0.06
-0.88%
Scisparc Ltd (SPRC) 最新ニュース
Scisparc Ltd (SPRC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Scisparc Ltd (SPRC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SciSparc shifts focus to agentic AI market - Investing.com
Scisparc Ltd (SPRC) Balance Sheet - TradingKey
Scisparc Ltd (SPRC) Institutional Confidence - TradingKey
SciSparc shifts focus to agentic AI market By Investing.com - Investing.com Canada
SciSparc targets agentic AI market and forms ad... - Pluang
Scisparc Ltd (SPRC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SciSparc Ltd. Targets Agentic AI Market and Plans Scientific Advisory Board for AI and Cybersecurity - Quiver Quantitative
SciSparc discusses agentic AI opportunities with several companies - Stock Titan
Scisparc Ltd (SPRC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Scisparc Ltd (SPRC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SciSparc Ltd. Revenue Breakdown – NASDAQ:SPRC - TradingView
SPRC|Scisparc Ltd|Price:5.330|Chg%:-0.390 - TradingKey
SciSparc Company Profile & Introduction - Moomoo
Scisparc Ltd (SPRC) Income Statement - TradingKey
SciSparc (SPRC) Stock Forecast & Analyst Ratings - Moomoo
SciSparc(SPRC) Stock Options Chain | Quotes & News - Moomoo
SciSparc Ltd. (Nasdaq: SPRC) starts Phase IIb SCI-110 trial for Tourette - Stock Titan
NeuroThera starts Phase IIb trial in Germany fo... - Pluang
SciSparc Subsidiary NeuroThera Initiates Phase IIb SCI-110 Clinical Trial Site at Hannover Medical School for Adult Tourette Syndrome - Quiver Quantitative
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb - GlobeNewswire
NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome - TheNewswire
Tourette treatment candidate SCI-110 enters testing at Hannover Medical School - Stock Titan
SciSparc (SPRC) Slips Over 7%: Support at $4.11 in Focus After Sharp DeclineWeak Sell Signals - dars.gov.et
SciSparc Ltd. (SPRC) details Alon Dayan RSUs and option in ownership update - Stock Titan
SciSparc Ltd. (SPRC) CEO Adler Oz updates Form 3 insider equity details - Stock Titan
SciSparc Ltd. (SPRC) director details RSU and option holdings in Form 3/A - Stock Titan
SciSparc Ltd. (SPRC) director revises Form 3, detailing RSU and option holdings - Stock Titan
SciSparc Ltd. (SPRC) CTO clarifies 5,528 RSU-linked shares and option terms - Stock Titan
SciSparc Ltd. (SPRC) director amends Form 3, details 3,649-share stake - Stock Titan
SciSparc Ltd. (SPRC) Tumbles 13.8% — Support Test in FocusRelative Volume - dars.gov.et
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
SciSparc (SPRC) Surges Over 10% as Trading Activity Picks UpOrder Block - dars.gov.et
SPRC Stock Price, Quote & Chart - ChartMill
NeuroThera Labs Announces Upsize to Private Placement - TheNewswire
NeuroThera Labs Announces C$5,000,000 Private Placement of Units - TheNewswire
SciSparc (SPRC) Drops 6.7% as Shares Approach Critical Support ZoneETF Creation Redemption - dars.gov.et
Form 144 SciSparc Ltd. For: 22 June By Investing.com - Investing.com Australia
[144] SciSparc Ltd. SEC Filing - Stock Titan
SciSparc (SPRC) Suffers Sharp Decline: Key Support Levels Under PressureVolume Breakout Ideas - dars.gov.et
Scisparc Ltd (SPRC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scisparc Ltd (SPRC) Valuation: PE, PB & Fair Value Analysis - TradingKey
SPRC News | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
Scisparc Ltd (SPRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SciSparc Ltd. (SPRC) Slips 2.46% as Shares Test Near-Term Support at $7.92Long Setup Ideas - dars.gov.et
SciSparc Ltd. Ordinary Shares Stock Short Interest Rises to 66.94% - Moomoo
SciSparc Ltd.'s Equity Buyback announced on July 7, 2022, has expired. - marketscreener.com
Why is SciSparc stock skyrocketing on Thursday? - MSN
SciSparc more than doubles as NeuroThera wins conditional nod for CliniQuantum deal - MSN
NeuroThera completes acquisition of 54% stake in CliniQuantum - Investing.com UK
In today's session, these stocks are experiencing unusual volume. - ChartMill
Which stocks are gapping on Thursday? - ChartMill
SPRC Stock Pops As SciSparc Pushes Into Quantum Clinical Analytics - timothysykes.com
SciSparc Subsidiary NeuroThera Labs Closes Majority Acquisition of CliniQuantum - TipRanks
These stocks that are showing activity before the opening bell on Thursday. - ChartMill
0.39%
1.94%
大文字化:
|
ボリューム (24 時間):